FIELD: medicine; ophthalmology.
SUBSTANCE: invention can be used to predict the response to anti-VEGF therapy in macular neovascularization. The presence of smoking, the presence of macular neovascularization in close relatives, and the presence of intraretinal edema are established. Each of them is assigned 1 if present, and 0 if absent. The height of the retinal pigment epithelium detachment in microns and the intraocular pressure in mmHg, measured by a non-contact method, are determined. Then, the predictive index for response to anti-VEGF therapy for macular neovascularization RESP_0 is calculated using the developed mathematical formula. An RESP_0 value of 0.5 or more predicts an unfavorable response to anti-VEGF therapy for macular neovascularization. When the RESP_0 value is less than 0.5, there is a favorable response to anti-VEGF therapy.
EFFECT: invention provides a personalized approach to indications for treatment with an anti-VEGF drug, which, in turn, will ensure the effectiveness of treatment of this disease.
1 cl, 2 ex
